Drug Trial Radar · NCT07793409
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
1,508
Planned (sponsor's estimate)
Start
Sep 16, 2026
Primary completion
Jul 23, 2031
Study completion Jul 23, 2031
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase 3, long-term safety extension study including participants of previous lunsekimig clinical trials with inadequately controlled chronic obstructive pulmonary disease (COPD ) characterized by an eosinophilic phenotype. The purpose of the LTS 18211 study is to characterize the long-term safety and efficacy of lunsekimig in adults with COPD who completed studies EFC18243 or EFC18244 in the main study, and to assess the impact of inhaled corticosteroids (ICS ) withdrawal in the ICS withdrawal sub-study. The study duration will be up to 100 weeks, including the following components: * Baseline Visit (Visit 1 / Week 0) will coincide with the End-of-Intervention visit from the parent study (EFC18243 or EFC18244) if possible * Treatment duration of up to 96 weeks * Safety follow-up period of approximately 4 weeks * The number of visits will be 26
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
LunsekimigDrug
* Pharmaceutical form: Solution for injection in prefilled syringe * Route of administration: Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exposure-adjusted incidence rate of treatment-emergent adverse events (TEAE), including adverse events of special interest (AESI ) and serious adverse events (SAE)Time frame: Study baseline to Week 100
- ICS withdrawal sub-study: Change from Week 12 (end of run-in period) to Week 36 in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1)Time frame: From Week 12 to Week 36
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
Newport Native MD- Site Number : 8403003
Newport Beach, California
Helix Biomedics- Site Number : 8403065
Boynton Beach, Florida
Innovations Biotech- Site Number : 8404019
Miami, Florida
Deluxe Health Center- Site Number : 8403010
Miami Lakes, Florida
Clinical Research Trials of Florida- Site Number : 8403011
Tampa, Florida
Private Practice - Dr. David Kavtaradze- Site Number : 8403006
Cordele, Georgia
Investigational Site Number : 0324005
Buenos Aires, Argentina
Investigational Site Number : 1243004
Guelph, Ontario, Canada
Investigational Site Number : 1244050
Saint-Charles-Borromée, Quebec, Canada
Investigational Site Number : 1244042
Victoriaville, Quebec, Canada
Investigational Site Number : 1523003
Santiago, Reg Metropolitana de Santiago, Chile
Investigational Site Number : 1564021
Huzhou, China
Investigational Site Number : 1564077
Luoyang, China
Investigational Site Number : 1563011
Xiangtan, China
Investigational Site Number : 8264017
Rotherham, United Kingdom
Investigational Site Number : 8264013
Chertsey, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.